Jessica Wickland, L. Steven Brown, Valerie Blanco, Roy Heyne, Christy Turer, Charles R. Rosenfeld
{"title":"Persistent high blood pressure and renal dysfunction in preterm infants during childhood","authors":"Jessica Wickland, L. Steven Brown, Valerie Blanco, Roy Heyne, Christy Turer, Charles R. Rosenfeld","doi":"10.1038/s41390-022-02083-y","DOIUrl":null,"url":null,"abstract":"Infants born very preterm (≤32 weeks gestational age, GA) and very-low birth weight (≤1500 g; PT-VLBW) demonstrate high systolic blood pressure (SBP), renal dysfunction, and obesity at 6 months–3 years and in early adulthood. Their parallel measurement and progression during childhood is unclear. We reenrolled 62/120 patients originally seen at 1–3 years at 10–13 years and remeasured anthropometric indices, SBP, and serum creatinine (Cr) and cystatin C (cysC) to determine estimated glomerular filtration rate (eGFR). We selected Term-matched Controls at 10–13 years from the 2015–2016 NHANES database at a ratio of 2 Controls:1 Case (124:62). Reenrolled patients were predominantly Hispanic, birth weight 1073 ± 251 g, and GA at birth 28 ± 2 weeks. At 10–13 years, 45% were classified overweight/obese, 48% had SBP ≥ 90th centile (77% considered hypertensive), and 34% had low eGFR (<90 mL min−1 [1.73 m2]−1). Notably, 57% of reenrolled PT-VLBW Cases had low eGFRcysC at both 1–3 and 10–13 years, P < 0.03. Compared to Controls, Cases had four times the adjusted odds for having an elevated SBP and low eGFRCr despite similar proportions with overweight/obesity among Cases and Controls. PT-VLBW infants seen at 1–3 years exhibit obesity, elevated SBP, and low eGFR in infancy and 10–13 years. Although the small sample size may limit conclusions, pediatricians should consider serial evaluations of PT-VLBW throughout childhood.","PeriodicalId":19829,"journal":{"name":"Pediatric Research","volume":"93 1","pages":"217-225"},"PeriodicalIF":3.1000,"publicationDate":"2022-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Research","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41390-022-02083-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Infants born very preterm (≤32 weeks gestational age, GA) and very-low birth weight (≤1500 g; PT-VLBW) demonstrate high systolic blood pressure (SBP), renal dysfunction, and obesity at 6 months–3 years and in early adulthood. Their parallel measurement and progression during childhood is unclear. We reenrolled 62/120 patients originally seen at 1–3 years at 10–13 years and remeasured anthropometric indices, SBP, and serum creatinine (Cr) and cystatin C (cysC) to determine estimated glomerular filtration rate (eGFR). We selected Term-matched Controls at 10–13 years from the 2015–2016 NHANES database at a ratio of 2 Controls:1 Case (124:62). Reenrolled patients were predominantly Hispanic, birth weight 1073 ± 251 g, and GA at birth 28 ± 2 weeks. At 10–13 years, 45% were classified overweight/obese, 48% had SBP ≥ 90th centile (77% considered hypertensive), and 34% had low eGFR (<90 mL min−1 [1.73 m2]−1). Notably, 57% of reenrolled PT-VLBW Cases had low eGFRcysC at both 1–3 and 10–13 years, P < 0.03. Compared to Controls, Cases had four times the adjusted odds for having an elevated SBP and low eGFRCr despite similar proportions with overweight/obesity among Cases and Controls. PT-VLBW infants seen at 1–3 years exhibit obesity, elevated SBP, and low eGFR in infancy and 10–13 years. Although the small sample size may limit conclusions, pediatricians should consider serial evaluations of PT-VLBW throughout childhood.
期刊介绍:
Pediatric Research publishes original papers, invited reviews, and commentaries on the etiologies of children''s diseases and
disorders of development, extending from molecular biology to epidemiology. Use of model organisms and in vitro techniques
relevant to developmental biology and medicine are acceptable, as are translational human studies